Effect of Furosemide on Obesity-induced Glomerular Hyperfiltration
Status:
Terminated
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Background: Obesity is associated with a high prevalence of chronic kidney disease. The
glomerular hyperfiltration associated with obesity may play a role in the pathogenesis of
obesity associated chronic kidney disease. Attenuation of hyperfiltration by pharmacological
means may slow down the development and progression of chronic renal failure. The
investigators have previously shown that acetazolamide, a proximally acting diuretic that
activates TGF by increasing solute delivery to the macula densa, abates glomerular
hyperfiltration. The present study was designed to test the hypothesis that this decrease in
hyperfiltration is specific to acetazolamide and not due to a non specific diuretic effect.
The aim of the present study is to evaluate the effects of the administration of furosemide
p.o. to subjects with severe obesity on glomerular hemodynamics.
Methods: Ten obese subjects will participate in the study. They will undergo measurement of
glomerular filtration rate (inulin clearance) (GFR), renal plasma flow (RPF) (p-aminohippuric
acid clearance), filtration fraction, fractional excretion of lithium (FE LI) and blood
pressure, before and after administration of oral furosemide 20 to 40 mg bid for 3 days. The
effects of furosemide on glomerular hemodynamics in obese subjects will be compared to the
previously studied effects of acetazolamide.